• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications are not effective for a lot of people suffering from depression. A customized treatment may be the solution.

Cue is an intervention platform that converts passively acquired sensor data from smartphones into personalized micro-interventions for improving mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to identify their feature predictors and reveal distinct features that deterministically change mood with time.

Predictors of Mood

Depression is a leading cause of mental illness across the world.1 Yet only half of those affected receive treatment. To improve the outcomes, doctors must be able to identify and treat patients with the highest likelihood of responding to certain treatments.

A customized depression treatment is one method to achieve this. Utilizing mobile phone sensors and an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from the treatments they receive. Two grants were awarded that total more than $10 million, they will make use of these technologies to identify biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

The majority of research to date has focused on clinical and sociodemographic characteristics. These include demographic factors such as age, gender and education, clinical characteristics such as the severity of symptoms and comorbidities and biological markers such as neuroimaging and genetic variation.

While many of these variables can be predicted from the data in medical records, only a few studies have utilized longitudinal data to determine the causes of mood among individuals. Few also take into account the fact that moods vary significantly between individuals. Therefore, it is crucial to develop methods which permit the analysis and measurement of individual differences between mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive treatment for depression evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can identify different patterns of behavior and emotions that differ between individuals.

In addition to these modalities, the team also developed a machine-learning algorithm to model the changing variables that influence each person's mood. The algorithm blends the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was associated with CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was weak, however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied widely among individuals.

Predictors of symptoms

Depression is among the most prevalent causes of disability1 yet it is often not properly diagnosed and treated. In addition, a lack of effective interventions and stigmatization associated with depressive disorders stop many individuals from seeking help.

To help with personalized treatment, it is essential to identify predictors of symptoms. Current prediction methods rely heavily on clinical interviews, which aren't reliable and only detect a few symptoms associated with depression.

Machine learning can increase the accuracy of diagnosis and treatment for depression by combining continuous digital behavior phenotypes gathered from smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression treatment history (Chessdatabase.Science) Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements and capture a wide variety of distinct behaviors and patterns that are difficult to document through interviews.

The study comprised University of California Los Angeles students with moderate to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical care depending on their depression severity. Participants who scored a high on the CAT-DI scale of 35 65 were allocated online support with the help of a peer coach. those with a score of 75 patients were referred to psychotherapy in person.

Participants were asked a series questions at the beginning of the study regarding their demographics and psychosocial traits. The questions covered age, sex, and education, financial status, marital status, whether they were divorced or not, current suicidal ideas, intent or attempts, and how often they drank. The CAT-DI was used to rate the severity of depression symptoms on a scale from zero to 100. CAT-DI assessments were conducted each week for those who received online support and every week for those who received in-person treatment.

Predictors of Treatment Reaction

Research is focusing on personalized depression alternative treatment for depression and anxiety. Many studies are aimed at identifying predictors, which will help doctors determine the most effective medications to treat each individual. Pharmacogenetics in particular uncovers genetic variations that affect the way that our bodies process drugs. This allows doctors select medications that will likely work best for each patient, reducing time and effort spent on trial-and error treatments and eliminating any adverse effects.

Another approach that is promising is to build models of prediction using a variety of data sources, combining the clinical information with neural imaging data. These models can be used to identify which variables are the most predictive of a particular outcome, like whether a medication will help with symptoms or mood. These models can also be used to predict a patient's response to an existing treatment, allowing doctors to maximize the effectiveness of the current treatment.

A new era of research uses machine learning methods, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables to improve predictive accuracy. These models have been demonstrated to be effective in predicting treatment outcomes, such as response to antidepressants. These techniques are becoming increasingly popular in psychiatry, and are likely to be the norm in future treatment.

Research into the underlying causes of depression continues, as well as ML-based predictive models. Recent findings suggest that the disorder is connected with neural dysfunctions that affect specific circuits. This suggests that an the treatment for depression will be individualized focused on therapies that target these neural circuits to restore normal function.

Internet-delivered interventions can be an option to accomplish this. They can offer a more tailored and individualized experience for patients. A study showed that an internet-based program improved symptoms and improved quality life for MDD patients. In addition, a controlled randomized study of a customized approach to treating depression showed sustained improvement and reduced side effects in a significant percentage of participants.

Predictors of side effects

In the treatment of depression, a major challenge is predicting and identifying the antidepressant that will cause minimal or zero side effects. Many patients have a trial-and error approach, using several medications prescribed until they find one that is safe and effective. Pharmacogenetics provides an exciting new method for an effective and precise approach to choosing antidepressant medications.

There are several predictors that can be used to determine the antidepressant to be prescribed, such as gene variations, phenotypes of patients such as gender or ethnicity and comorbidities. To determine the most reliable and valid predictors for a specific treatment, controlled trials that are randomized with larger numbers of participants will be required. This is due to the fact that the identification of interactions or moderators could be more difficult in trials that only take into account a single episode of treatment centre for depression per patient, rather than multiple episodes of treatment over a period of time.

Furthermore the prediction of a patient's reaction to a specific medication will also likely require information on the symptom profile and comorbidities, as well as the patient's personal experiences with the effectiveness and tolerability of the medication. Currently, only a few easily assessable sociodemographic variables and clinical variables are reliably related to response to MDD. These include gender, age, race/ethnicity as well as BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to depression psychological treatment for depression is still in its early stages and there are many obstacles to overcome. It is crucial to have a clear understanding and definition of the genetic factors that cause depression, as well as an accurate definition of an accurate predictor of treatment response. Ethics such as privacy and the responsible use genetic information should also be considered. In the long run the use of pharmacogenetics could be a way to lessen the stigma that surrounds mental health treatment and improve treatment outcomes for those struggling with depression. As with all psychiatric approaches it is crucial to take your time and carefully implement the plan. In the moment, it's ideal to offer patients a variety of medications for depression that are effective and encourage them to talk openly with their physicians.